These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 29076637)

  • 1. Adjunctive therapies in Kawasaki disease.
    Tremoulet AH
    Int J Rheum Dis; 2018 Jan; 21(1):76-79. PubMed ID: 29076637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of intravenous immunoglobulin in the treatment of Kawasaki disease.
    Lo MS; Newburger JW
    Int J Rheum Dis; 2018 Jan; 21(1):64-69. PubMed ID: 29205910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
    Li X; Tang Y; Ding Y; Chen Y; Hou M; Sun L; Qian G; Qin L; Lv H
    Eur J Pharmacol; 2021 May; 899():173985. PubMed ID: 33652059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of glucocorticoids in Kawasaki disease.
    Miura M
    Int J Rheum Dis; 2018 Jan; 21(1):70-75. PubMed ID: 29105310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.
    Iio K; Morikawa Y; Miyata K; Kaneko T; Misawa M; Yamagishi H; Miura M
    J Pediatr; 2022 Jan; 240():158-163.e4. PubMed ID: 34461064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
    Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose aspirin for Kawasaki disease: outdated myth or effective aid?
    Amarilyo G; Koren Y; Brik Simon D; Bar-Meir M; Bahat H; Helou MH; Mendelson A; Hezkelo N; Chodick G; Berkun Y; Eisenstein E; Butbul Aviel Y; Barkai G; Bolkier Y; Padeh S; Brik R; Hashkes PJ; Harel L; Uziel Y
    Clin Exp Rheumatol; 2017; 35 Suppl 103(1):209-212. PubMed ID: 28079513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
    Roberts SC; Jain S; Tremoulet AH; Kim KK; Burns JC; ; Anand V; Anderson M; Ang J; Ansusinha E; Arditi M; Ashouri N; Bartlett A; Chatterjee A; DeBiasi R; Dekker C; DeZure C; Didion L; Dominguez S; El Feghaly R; Erdem G; Halasa N; Harahsheh A; Jackson MA; Jaggi P; Jain S; Jone PN; Kaushik N; Kurio G; Lillian A; Lloyd D; Manaloor J; McNelis A; Michalik DE; Newburger J; Newcomer C; Perkins T; Portman M; Romero J; Ronis T; Rowley A; Schneider K; Schuster J; Tejtel SKS; Sharma K; Simonsen K; Szmuszkovicz J; Truong D; Wood J; Yeh S
    Contemp Clin Trials; 2019 Apr; 79():98-103. PubMed ID: 30840903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM; Silverman ED; McCrindle BW; Yeung RS
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as a novel predictor of intravenous immunoglobulin resistance in patients with Kawasaki disease: a multicenter study.
    Kanai T; Takeshita S; Kawamura Y; Kinoshita K; Nakatani K; Iwashima S; Takizawa Y; Hirono K; Mori K; Yoshida Y; Nonoyama S
    Heart Vessels; 2020 Oct; 35(10):1463-1472. PubMed ID: 32449049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
    Chan H; Chi H; You H; Wang M; Zhang G; Yang H; Li Q
    BMC Pediatr; 2019 May; 19(1):158. PubMed ID: 31101091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
    Lim YJ; Jung JW
    Yonsei Med J; 2014 Sep; 55(5):1260-6. PubMed ID: 25048483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
    Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
    EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease.
    Berdej-Szczot E; Małecka-Tendera E; Gawlik T; Firek-Pędras M; Szydłowski L; Gawlik A
    Kardiol Pol; 2017; 75(3):261-266. PubMed ID: 27995598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
    Han CL; Zhao SL
    Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunct cyclosporine therapy for refractory Kawasaki disease in a very young infant.
    Okada S; Azuma Y; Suzuki Y; Yamada H; Wakabayashi-Takahara M; Korenaga Y; Akase H; Hasegawa S; Ohga S
    Pediatr Int; 2016 Apr; 58(4):295-8. PubMed ID: 26670024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Kawasaki disease in adult patients].
    Sève P; Lega JC
    Rev Med Interne; 2011 Jan; 32(1):17-25. PubMed ID: 20537446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial.
    Fukui S; Seki M; Minami T; Kotani K; Oka K; Yokomizo A; Matsubara D; Sato T; Nozaki Y; Saito M; Kikuchi Y; Miyamoto K; Monden Y; Yamagata T
    Pediatr Rheumatol Online J; 2021 Jul; 19(1):107. PubMed ID: 34217297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
    Hamada H; Suzuki H; Onouchi Y; Ebata R; Terai M; Fuse S; Okajima Y; Kurotobi S; Hirai K; Soga T; Ishiguchi Y; Okuma Y; Takada N; Yanai M; Sato J; Nakayashiro M; Ayusawa M; Yamamoto E; Nomura Y; Hashimura Y; Ouchi K; Masuda H; Takatsuki S; Hirono K; Ariga T; Higaki T; Otsuki A; Terauchi M; Aoyagi R; Sato T; Fujii Y; Fujiwara T; Hanaoka H; Hata A;
    Lancet; 2019 Mar; 393(10176):1128-1137. PubMed ID: 30853151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
    Wang Y; Wang W; Gong F; Fu S; Zhang Q; Hu J; Qi Y; Xie C; Zhang Y
    Arthritis Rheum; 2013 Mar; 65(3):805-14. PubMed ID: 23440694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.